Turn Therapeutics Inc. Professional Fees
Turn Therapeutics Inc. (TTRX) reported Professional Fees of $272.02 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProfessionalFees · last filed 2026-08-12
- Turn Therapeutics Inc. professional fees for the quarter ending 2026-06-30 was $272.02K, a 72.74% decline year-over-year.
- Turn Therapeutics Inc. professional fees for the quarter ending 2026-03-31 was $303.67K, a 334.66% increase year-over-year.
- Turn Therapeutics Inc. professional fees for the quarter ending 2025-12-31 was $893.46K, a 766.29% increase year-over-year.
- Turn Therapeutics Inc. professional fees for the quarter ending 2025-09-30 was $1.36M, a 1935.71% increase year-over-year.
- Turn Therapeutics Inc. professional fees for fiscal 2025 was $3.32M, a 813.27% increase from fiscal 2024.
- Turn Therapeutics Inc. professional fees for fiscal 2024 was $364.01K.
| Period end | Professional Fees 3 month | Professional Fees 6 month | Professional Fees 9 month | Professional Fees 12 month |
|---|---|---|---|---|
| 2026-06-30 | $272.02K 10-Q · filed 2026-08-12 | $575.70K 10-Q · filed 2026-08-12 | $1.47M derived: sum of 3 quarters · filed 2026-08-12 | $2.83M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $303.67K 10-Q · filed 2026-05-11 | $1.20M derived: sum of 2 quarters · filed 2026-05-11 | $2.56M derived: sum of 3 quarters · filed 2026-05-11 | $3.56M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $893.46K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.26M derived: sum of 2 quarters · filed 2026-03-31 | $3.25M derived: sum of 3 quarters · filed 2026-08-12 | $3.32M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.36M 10-Q · filed 2025-11-13 | $2.36M derived: sum of 2 quarters · filed 2026-08-12 | $2.43M 10-Q · filed 2025-11-13 | $2.53M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $997.86K 10-Q · filed 2026-08-12 | $1.07M 10-Q · filed 2026-08-12 | $1.17M derived: sum of 3 quarters · filed 2026-08-12 | $1.24M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $69.86K 10-Q · filed 2026-05-11 | $173.00K derived: sum of 2 quarters · filed 2026-05-11 | $239.96K derived: sum of 3 quarters · filed 2026-05-11 | |
| 2024-12-31 | $103.14K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $170.10K derived: sum of 2 quarters · filed 2026-03-31 | $364.01K 10-K · filed 2026-03-31 | |
| 2024-09-30 | $66.96K 10-Q · filed 2025-11-13 | $260.87K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |